Incyte Biosciences Distribution B.V. withdrew its application for a marketing authorisation of Zynyz for the treatment of squamous carcinoma of the anal canal, a cancer of the tissues of the anus. The company withdrew the application on 8 October 2021.
Therapeutic Indication
### Therapeutic indication Zynyz is indicated as monotherapy for the first-line treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) not amenable to curative surgery or radiation therapy.
Therapeutic Area (MeSH)
N/AATC Code
L01FF10
ATC Item
retifanlimab
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
N/AEMA Name
Zynyz
Medicine Name
Zynyz
Aliases
N/ANo risk management plan link.
